157 related articles for article (PubMed ID: 34065481)
21. Serum Human Epididymis Protein 4 is Associated with Renal Function and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus.
Zhang M; Zhao B; Xie J; Liang Y; Yang Z
Biomed Res Int; 2019; 2019():4831459. PubMed ID: 31815140
[TBL] [Abstract][Full Text] [Related]
22. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4.
Han KH; Park NH; Kim JJ; Kim S; Kim HS; Lee M; Song YS
J Gynecol Oncol; 2019 Nov; 30(6):e83. PubMed ID: 31576682
[TBL] [Abstract][Full Text] [Related]
23. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
[TBL] [Abstract][Full Text] [Related]
25. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic performance of HE4 and ROMA among Chinese women.
Shen Y; Zhao L; Lu S
Clin Chim Acta; 2020 Jan; 500():42-46. PubMed ID: 31626761
[TBL] [Abstract][Full Text] [Related]
27. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
28. HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.
Langmár Z; Németh M; Vleskó G; Király M; Hornyák L; Bösze P
Eur J Gynaecol Oncol; 2011; 32(6):605-10. PubMed ID: 22335019
[TBL] [Abstract][Full Text] [Related]
29. An Array SPRi Biosensor for the Determination of Follicle-Stimulating Hormone in Blood Plasma.
Sankiewicz A; Zelazowska-Rutkowska B; Lukaszewski Z; Hermanowicz A; Gorodkiewicz E
Sensors (Basel); 2023 Dec; 23(24):. PubMed ID: 38139531
[TBL] [Abstract][Full Text] [Related]
30. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
31. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
[TBL] [Abstract][Full Text] [Related]
32. A Self-Calibrating IoT Portable Electrochemical Immunosensor for Serum Human Epididymis Protein 4 as a Tumor Biomarker for Ovarian Cancer.
Bianchi V; Mattarozzi M; Giannetto M; Boni A; De Munari I; Careri M
Sensors (Basel); 2020 Apr; 20(7):. PubMed ID: 32260240
[TBL] [Abstract][Full Text] [Related]
33. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer.
Kim B; Park Y; Kim B; Ahn HJ; Lee KA; Chung JE; Han SW
J Clin Lab Anal; 2019 Jan; 33(1):e22624. PubMed ID: 30009497
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
Schummer M; Drescher C; Forrest R; Gough S; Thorpe J; Hellström I; Hellström KE; Urban N
Gynecol Oncol; 2012 Apr; 125(1):65-9. PubMed ID: 22155417
[TBL] [Abstract][Full Text] [Related]
36. Serum HE4 as a diagnostic and prognostic marker for lung cancer.
Iwahori K; Suzuki H; Kishi Y; Fujii Y; Uehara R; Okamoto N; Kobayashi M; Hirashima T; Kawase I; Naka T
Tumour Biol; 2012 Aug; 33(4):1141-9. PubMed ID: 22373583
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
[TBL] [Abstract][Full Text] [Related]
38. An ultrasensitive ratiometric electrochemiluminescence immunosensor combining photothermal amplification for ovarian cancer marker detection.
Fang D; Zhang S; Dai H; Lin Y
Biosens Bioelectron; 2019 Dec; 146():111768. PubMed ID: 31606687
[TBL] [Abstract][Full Text] [Related]
39. BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.
Abdelrazek MA; Nageb A; Barakat LA; Abouzid A; Elbaz R
Breast Cancer; 2022 May; 29(3):507-515. PubMed ID: 34994942
[TBL] [Abstract][Full Text] [Related]
40. HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer.
Espiau Romera A; Cuesta Guardiola T; Benito Vielba M; De Bonrostro Torralba C; Coronado Martín PJ; Baquedano Mainar L
Int J Gynaecol Obstet; 2020 Jun; 149(3):265-268. PubMed ID: 32147821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
